🇺🇸 FDA
Company

Corvus

Corvus Pharmaceuticals

CRVS pharma USA

Quick answer

Corvus is a pharma company (CRVS) headquartered in SOUTH SAN FRANCISCO, CA, USA with 9 tracked pipeline programs.

Pipeline (9)

project

CPI-006 2 mg/kg + SOC

Covid-19

Phase 3 · small_molecule · terminated

1 trials project

Soquelitinib

Peripheral T-Cell Lymphoma, Not Otherwise Specified

Phase 3 · small_molecule · active

1 trials project

Soquelitinib

Atopic Dermatitis

Phase 2 · small_molecule · active

2 trials project

CPI-006

Non-Small Cell Lung Cancer

Phase 1 · small_molecule · completed

1 trials project

CPI-006

COVID-19

Phase 1 · small_molecule · completed

1 trials project

CPI-444 Capsules

Healthy Subjects

Phase 1 · small_molecule · completed

1 trials project

CPI-818

T-cell Lymphoma

Phase 1 · small_molecule · active

1 trials project

Ciforadenant

Multiple Myeloma

Phase 1 · small_molecule · completed

1 trials project

Ciforadenant

Renal Cell Cancer

Phase 1 · small_molecule · completed

1 trials

Patents (8)

patent

US 12351644

Anti-CD73 antibodies

Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12174192

Methods for detecting and treating cancers having adenosine pathway activation

Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12116635

Methods for detecting and treating cancers having adenosine pathway activation

Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12023337

Methods of treating cancer

Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11897874

Compounds and methods for modulating Interleukin-2-inducible T-cell kinase

Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11859007

Humanized anti-CD73 antibodies

Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11266649

Pharmaceutical formulations

Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11254686

Compounds and methods for modulating adenosine A2B receptor and adenosine A2A re

Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)